INS and Hypoglycemia: Indeed, compared to NPH, basal insulin analogues have been shown to reduce the incidence of hypoglycemia (especially nocturnal) and weight gain—two main adverse effects that may be associated with intensifying diabetes treatment, and are a concern for both patients and physicians [6].